We’re here for the cure. Everything we do is to move us closer to our goal, of finding new treatments to slow, stop or reverse the progression of Parkinson’s. Your donations and your involvement in research will lead to the breakthrough we all want to see.
Curing Parkinson’s needs world-class collaborative science involving researchers, clinicians, the pharmaceutical industry and, most importantly, people who are living with Parkinson’s. This collaboration is at the heart of our research programme.
Our leadership and funding enables the world’s leading neuroscientists and neurologists to prioritise, together, the next generation of drugs for clinical trial. We’re acting with urgency, for people currently living with Parkinson’s, with a focus on research which has potential to translate into the clinic within five years.
In August 2020, one third of disease-modifying trials that are underway had been evaluated by our International Linked Clinical Trials (iLCT) programme. Drugs evaluated by the Cure Parkinson’s team, found to have the potential to slow, stop or reverse Parkinson’s, account for 35% of curative research trials globally. More than 10% of all global disease-modifying trials are being funded by Cure Parkinson’s.
As reported in the Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
We’ve made significant progress towards our goal. As well as reshaping the approach to Parkinson’s research, we’ve directly funded, or secured funding, for over £75 million of clinical trials searching for a cure for Parkinson’s. But there’s so much more that we need to do.